Clinical spectrum and prognostic impact of cancer in critically ill patients with HIV: a multicentre cohort study.
Cancer
Human immunodeficiency virus
Intensive care unit
Outcome
Treatment limitation decision
Journal
Annals of intensive care
ISSN: 2110-5820
Titre abrégé: Ann Intensive Care
Pays: Germany
ID NLM: 101562873
Informations de publication
Date de publication:
22 Aug 2023
22 Aug 2023
Historique:
received:
04
06
2023
accepted:
04
08
2023
medline:
23
8
2023
pubmed:
23
8
2023
entrez:
22
8
2023
Statut:
epublish
Résumé
Both AIDS-defining and non-AIDS-defining cancers (ADC/NADC) predispose people living with HIV (PLHIV) to critical illnesses. The objective of this multicentre study was to investigate the prognostic impact of ADC and NADC in PLHIV admitted to the intensive care unit (ICU). All PLHIV admitted over the 2015-2020 period in 12 university-affiliated ICUs in France were included in the study cohort. The effect of ADC and NADC on in-hospital mortality (primary study endpoint) was measured through logistic regression with augmented backward elimination of potential independent variables. The association between ADC/NADC and treatment limitation decision (TLD) during the ICU stay (secondary study endpoint) was analysed. One-year mortality in patients discharged alive from the index hospital admission (exploratory study endpoint) was compared between those with ADC, NADC or no cancer. Amongst the 939 included PLHIV (median age, 52 [43-59] years; combination antiretroviral therapy, 74.4%), 97 (10.3%) and 106 (11.3%) presented with an active NADC (mostly lung and intestinal neoplasms) and an active ADC (predominantly AIDS-defining non-Hodgkin lymphoma), respectively. Inaugural admissions were common. Bacterial sepsis and non-infectious neoplasm-related complications accounted for most of admissions in these subgroups. Hospital mortality was 12.4% in patients without cancer, 30.2% in ADC patients and 45.4% in NADC patients (P < 0.0001). NADC (adjusted odds ratio [aOR], 7.00; 95% confidence interval [CI], 4.07-12.05) and ADC (aOR, 3.11; 95% CI 1.76-5.51) were independently associated with in-hospital death after adjustment on severity and frailty markers. The prevalence of TLD was 8.0% in patients without cancer, 17.9% in ADC patients and 33.0% in NADC patients (P < 0.0001)-organ failures and non-neoplastic comorbidities were less often considered in patients with cancer. One-year mortality in survivors of the index hospital admission was 7.8% in patients without cancer, 17.0% in ADC patients and 33.3% in NADC patients (P < 0.0001). NADC and ADC are equally prevalent, stand as a leading argument for TLD, and strongly predict in-hospital death in the current population of PLHIV requiring ICU admission.
Sections du résumé
BACKGROUND
BACKGROUND
Both AIDS-defining and non-AIDS-defining cancers (ADC/NADC) predispose people living with HIV (PLHIV) to critical illnesses. The objective of this multicentre study was to investigate the prognostic impact of ADC and NADC in PLHIV admitted to the intensive care unit (ICU).
METHODS
METHODS
All PLHIV admitted over the 2015-2020 period in 12 university-affiliated ICUs in France were included in the study cohort. The effect of ADC and NADC on in-hospital mortality (primary study endpoint) was measured through logistic regression with augmented backward elimination of potential independent variables. The association between ADC/NADC and treatment limitation decision (TLD) during the ICU stay (secondary study endpoint) was analysed. One-year mortality in patients discharged alive from the index hospital admission (exploratory study endpoint) was compared between those with ADC, NADC or no cancer.
RESULTS
RESULTS
Amongst the 939 included PLHIV (median age, 52 [43-59] years; combination antiretroviral therapy, 74.4%), 97 (10.3%) and 106 (11.3%) presented with an active NADC (mostly lung and intestinal neoplasms) and an active ADC (predominantly AIDS-defining non-Hodgkin lymphoma), respectively. Inaugural admissions were common. Bacterial sepsis and non-infectious neoplasm-related complications accounted for most of admissions in these subgroups. Hospital mortality was 12.4% in patients without cancer, 30.2% in ADC patients and 45.4% in NADC patients (P < 0.0001). NADC (adjusted odds ratio [aOR], 7.00; 95% confidence interval [CI], 4.07-12.05) and ADC (aOR, 3.11; 95% CI 1.76-5.51) were independently associated with in-hospital death after adjustment on severity and frailty markers. The prevalence of TLD was 8.0% in patients without cancer, 17.9% in ADC patients and 33.0% in NADC patients (P < 0.0001)-organ failures and non-neoplastic comorbidities were less often considered in patients with cancer. One-year mortality in survivors of the index hospital admission was 7.8% in patients without cancer, 17.0% in ADC patients and 33.3% in NADC patients (P < 0.0001).
CONCLUSIONS
CONCLUSIONS
NADC and ADC are equally prevalent, stand as a leading argument for TLD, and strongly predict in-hospital death in the current population of PLHIV requiring ICU admission.
Identifiants
pubmed: 37608140
doi: 10.1186/s13613-023-01171-4
pii: 10.1186/s13613-023-01171-4
pmc: PMC10444715
doi:
Types de publication
Journal Article
Langues
eng
Pagination
74Informations de copyright
© 2023. La Société de Réanimation de Langue Francaise = The French Society of Intensive Care (SRLF).
Références
Blood. 2022 Feb 17;139(7):995-1012
pubmed: 34469512
Eur J Haematol. 2021 Jun;106(6):788-799
pubmed: 33624346
J Acquir Immune Defic Syndr. 2013 Jan 1;62(1):52-9
pubmed: 23111572
Lancet Infect Dis. 2015 Jul;15(7):810-8
pubmed: 26070969
Chest. 2009 Jan;135(1):11-17
pubmed: 18719058
JAMA. 2023 Jan 3;329(1):63-84
pubmed: 36454551
Lancet. 2014 Jul 19;384(9939):241-8
pubmed: 25042234
Crit Care. 2010;14(4):R152
pubmed: 20698966
Leuk Lymphoma. 2016 Aug;57(8):1831-8
pubmed: 26758791
Eur J Emerg Med. 2022 Jun 1;29(3):221-226
pubmed: 35297386
J Crit Care. 2019 Oct;53:207-211
pubmed: 31271956
PLoS One. 2016 Feb 12;11(2):e0148955
pubmed: 26871709
Clin Infect Dis. 2018 Jun 18;67(1):50-57
pubmed: 29325033
Am J Respir Crit Care Med. 1998 Oct;158(4):1163-7
pubmed: 9769276
Ann Intern Med. 2018 Jun 19;168(12):866-873
pubmed: 29801099
JAMA. 2019 Nov 05;322(17):1692-1704
pubmed: 31577037
Lancet HIV. 2018 Sep;5(9):e524-e530
pubmed: 30025682
Intensive Care Med. 2020 Feb;46(2):329-342
pubmed: 32016535
Crit Care. 2014 Aug 27;18(4):475
pubmed: 25159592
AIDS Care. 2023 Oct;35(10):1587-1589
pubmed: 36226381
Cancer Epidemiol Biomarkers Prev. 2021 Mar;30(3):554-563
pubmed: 33310788
Crit Care Med. 2010 Jul;38(7):1530-5
pubmed: 20453644
Crit Care Med. 2009 May;37(5):1605-11
pubmed: 19325488
Intensive Care Med. 2014 Dec;40(12):1906-15
pubmed: 25236542
Crit Care Med. 2019 Oct;47(10):1310-1316
pubmed: 31356477
AIDS Care. 2023 May;35(5):753-763
pubmed: 35578401
Lancet HIV. 2017 Nov;4(11):e495-e504
pubmed: 28803888
Chest. 2021 Oct;160(4):1560-1564
pubmed: 33961832
Leuk Lymphoma. 2013 Aug;54(8):1724-9
pubmed: 23185988
PLoS One. 2014 Nov 21;9(11):e113677
pubmed: 25415265
Leuk Lymphoma. 2015 May;56(5):1240-5
pubmed: 25098426
Lancet Oncol. 2021 Jun;22(6):e240-e253
pubmed: 34087151
J Clin Epidemiol. 2008 Apr;61(4):344-9
pubmed: 18313558
Lancet Public Health. 2017 Jan;2(1):e35-e46
pubmed: 29249478
Int J Cardiol. 2015 Dec 15;201:302-7
pubmed: 26301665
J Infect Dev Ctries. 2023 Jan 31;17(1):102-110
pubmed: 36795933
Crit Care. 2023 Mar 13;27(1):108
pubmed: 36915207
Clin Infect Dis. 2021 May 4;72(9):e224-e231
pubmed: 32710777
AIDS Care. 2015;27(3):370-7
pubmed: 25307722
Ann Intensive Care. 2018 Aug 4;8(1):80
pubmed: 30076547
Chest. 2020 Feb;157(2):293-309
pubmed: 31421114
J Infect. 2011 Apr;62(4):301-8
pubmed: 21329724
JAMA. 2003 Aug 13;290(6):790-7
pubmed: 12915432
Lancet HIV. 2022 Oct;9(10):e700-e708
pubmed: 36179753
Intensive Care Med. 2009 Oct;35(10):1678-86
pubmed: 19575179
Biom J. 2018 May;60(3):431-449
pubmed: 29292533
Ann Intensive Care. 2019 Oct 2;9(1):110
pubmed: 31578641
Clin Infect Dis. 2013 Dec;57(11):1638-47
pubmed: 23899679
Ann Am Thorac Soc. 2020 Apr;17(4):466-473
pubmed: 31800299